IDH2 and astrocytoma (excluding glioblastoma): On the other hand, Dono et al. showed excellent overall sensitivity and specificity of MTAP IHC test results as a surrogate of CDKN2A homozygous deletion presence (92.3% and 97.5%, respectively) in meningiomas and IDH-mutant astrocytomas [16].